Hero - CBD vs CBG vs CBN
Home/Compare/CBD vs CBG vs CBN

CBD vs CBG vs CBN: The Three Compared Side by Side

All three are non-intoxicating and all three are sold as if they were interchangeable wellness options. They are not. CBD works mostly outside the cannabinoid receptor system. CBG’s most potent action is at adrenergic receptors. CBN is a breakdown product of THC. Their evidence bases differ even more than their pharmacology: CBD has dozens of human trials, CBG has one, and CBN has one that missed its primary endpoint.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
CBD
CBG
CBN
Where it comes from
CBDA, a deliberate plant product
CBGA, the parent of all cannabinoids
Oxidation of THC. Not a plant product
CB1 receptor
No activation. Negative allosteric modulator
Weak, Ki around 1.3 μM. Antagonist at high concentration
Weak partial agonist, maximum effect 29 percent
CB2 receptor
Ki 240 nM, low efficacy
Weak partial agonist, Ki 490 nM
Negligible
Most potent measured target
ENT1 adenosine transporter, Ki under 250 nM
Alpha-2 adrenoceptor, EC50 0.2 nM
TRPA1, EC50 0.18 μM
Serotonin 5-HT1A
Weak agonist
Antagonist, KB 51.9 nM
Not a notable target
Intoxicating
No
No
Weakly, at very high doses
Active metabolite
7-OH-CBD, less potent
Not characterized
11-OH-CBN, roughly THC-strength at CB1
Human trials
Dozens, including three regulatory-grade
One, n=34, 20 mg
One, n=20, primary endpoint failed
Human pharmacokinetics
Partially characterized
None published
None published
Approved medicine
Epidiolex
None
None
Typical cost per mg
Lowest
Highest
High

How each one is made

Cannabis builds one precursor, CBGA, then splits it three ways using three competing enzymes. THCA synthase makes THCA. CBDA synthase makes CBDA. CBCA synthase makes CBCA.

CBD is what CBDA becomes when it loses a carbon dioxide group to heat and time.

CBG is what is left of CBGA when the synthases have not consumed it. This is why CBG is scarce in most cultivars and why CBG products cost more. It is a botany problem, not a potency signal.

CBN is not on that diagram at all. It has no synthase. It forms when THC sits in contact with oxygen, heat and light and degrades. High CBN means old or heat-treated material. Concentrated CBN products are made by deliberately degrading THC.

That last point deserves emphasis, because it is the honest answer to why the three are not really peers. Two are plant products. One is a decay product.

Three different mechanisms

Inner - CBD vs CBG vs CBN

CBD does very little at cannabinoid receptors. The FDA’s Epidiolex label says outright that cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors. Its genuinely potent action is blocking the ENT1 adenosine transporter, below 250 nanomolar. It also hits TRPA1 hard, at 0.09 micromolar, and has activity at TRPV1, 5-HT1A and GPR55. A 2015 systematic review of over 65 reported CBD targets concluded most are only reached at concentrations people never achieve.

CBG has the single most potent number of the three. A 2010 study found alpha-2 adrenoceptor agonism at an EC50 of 0.2 nanomolar in mouse brain membranes. That is the receptor family clonidine acts on. The same paper found the effect much weaker in isolated tissue, so its physiological relevance is unresolved. CBG is also a 5-HT1A antagonist, which is the opposite direction to CBD at the same receptor.

CBN is a weak partial agonist at CB1, roughly 29 percent maximum effect against THC’s 72 percent. The more interesting finding is that its metabolite, 11-OH-CBN, reaches equivalent brain concentrations and behaves like THC at CB1. If CBN does anything centrally, that metabolite is probably responsible.

The evidence gap is the real story

CBD
Strong human evidence in three rare epilepsy syndromes, at doses of roughly 700 to 1,400 mg a day for an adult.
Weak or negative evidence elsewhere: 15 of 16 randomized pain trials with verified pharmaceutical CBD showed no benefit over placebo.
A modest anxiety signal in meta-analysis at 300 to 800 mg acute doses.
No adequate sleep trial base.
CBG
One placebo-controlled trial, published 2024, 34 healthy adults, 20 mg, conducted by video call.
Reduced reported anxiety and stress, better verbal memory, no impairment.
Everything else on CBG is in vitro or rodent.
CBN
One trial, published 2026, 20 adults with diagnosed insomnia, overnight polysomnography, 30 mg and 300 mg.
The primary endpoint failed: time spent awake during the night was not significantly reduced.
Some secondary measures improved at 300 mg only.
Consumer CBN products contain 1 to 5 mg, sixty to three hundred times less.

Notice that the compound with the most marketing energy behind it, CBN, has the weakest supporting result.

What people get wrong

01Take all three for the entourage effect.
The entourage hypothesis, as used in marketing, has not survived the experiments designed to test it. Two independent studies found cannabis terpenes do not bind cannabinoid receptors and do not modulate THC or CBD activity there. A 2024 scoping review found limited evidence for it as a stable phenomenon. Real cannabinoid interactions tend to be pharmacokinetic rather than synergistic at receptors.
02CBG is the mother cannabinoid so it is the most powerful.
Being upstream in a biosynthetic pathway says nothing about what a molecule does in your body.
03CBN is nature's sleep aid.
The claim traces to folklore about aged cannabis, not to research.
04They are all basically the same thing.
They act at different receptors, in different directions, with different evidence.

Choosing between them

We are not able to recommend any of these for a health condition, and we would not want to. What we can do is set out what is actually known so the choice is yours to make with the facts visible.

If you want the most researched option, that is CBD, by a wide margin, though the research is not uniformly positive.

If you find the pharmacology interesting and accept the uncertainty, CBG has the most striking receptor number and one supportive small study.

If you are considering CBN for sleep, understand that the one human trial missed its primary endpoint and used a dose far above what is sold. That is worth knowing before you pay a premium for it.

Still weighing up the options? See CBG vs CBD, CBN vs CBD or CBG vs CBN. For more background, read our guide on CBD for sleep. Endoca products related to this comparison: CBN products.

How Endoca tests for this

All three appear on every Endoca certificate of analysis, alongside CBDA, CBC, THC and THCA, tied to the batch code on your bottle. We publish the CBN number even when it is low, because low CBN in a CBD product means the material was extracted and stored well. Numbers on a lab report are the only claim about cannabinoid content that means anything.

Frequently asked questions

They are commonly combined and no interaction problem is documented. There is no evidence that the combination outperforms any of them alone.

They are not on the same scale. CBG has the most potent single receptor number. CBD has the most human evidence. CBN is the only one that is weakly intoxicating at very high doses.

The plant converts nearly all of its CBGA into other cannabinoids. Harvesting CBG means sacrificing yield.

Usually a small amount, and it rises as the product ages.

Full-spectrum hemp extract typically contains CBD, CBDA, CBG, CBC and small amounts of CBN and THC. The certificate of analysis gives the actual figures.

None has strong human evidence for sleep. CBN is the one most marketed for sleep, and the trials so far are small with mixed results. CBD has more human research overall, but sleep was rarely the main outcome.

CBN forms when THC breaks down and is a weak CB1 agonist, far weaker than THC. At the amounts found in CBD and CBN products it is not considered intoxicating, though high isolated doses are less well studied.

References

01

Cascio MG et al. Cannabigerol is a highly potent alpha-2-adrenoceptor agonist. Br J Pharmacol 2010;159:129-141.

02

Cuttler C et al. Acute effects of cannabigerol on anxiety, stress and mood. Sci Rep 2024;14:16163.

03

Lavender I et al. The effects of cannabinol on sleep in insomnia disorder. J Sleep Res 2026;35:e70284.

04

Arnold JC et al. Cannabinol and its metabolite 11-OH-CBN. Neuropsychopharmacology 2025;50:586-595.

05

Ibeas Bih C et al. Molecular Targets of Cannabidiol. Neurotherapeutics 2015;12:699-730.

06

Moore RA et al. Cannabidiol (CBD) for Pain. J Pain 2024;25:833-842.

07

Finlay DB et al. Terpenoids From Cannabis Do Not Mediate an Entourage Effect. Front Pharmacol 2020;11:359.

08

Zagzoog A et al. Minor phytocannabinoid pharmacology. Sci Rep 2020;10:20405.

Last reviewed 1 September 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.